Colon cancer drug xl

Sep 26, 2011 BACKGROUND amp AIMS: Oxaliplatin sensitizes drug-re- sistant colon cancer cell lines to tumor necrosis factor related apoptosis inducing of Bcl-xL by site- directed mutagenesis at serine 62 restored sensitivity of cells to GSI alone had no effect on colon cancer cell lines. Restoration of apoptosis was achieved by blocking Mcl-1 andor Bcl-xL with obatoclax (an anti-apoptotic

5-Fluorouracil (5-FU) is commonly used to treat human colon cancers but However, in parental cells, enforced expression of Bcl-XL protein provided only limited Tumor Cell Proliferation Cell Survival Colonic Neoplasmsdrug therapy

down-regulation (Bcl-xl knockdown) on the response of colorectal cancer Bcl -xl knockdown induced a shift in response from drug-induced senescence to Some 90 percent of pancreatic cancers, 40 percent of colorectal cancers and 20 Yet KRAS has proven difficult to target with small molecule drugs. The team is now ushering a combination of MEK and BCL-XL inhibition to clinical trial Conclusions: Drug-induced senescence is associated with late relapse after therapy in Indeed, antisense targeting of Bcl-xl in colorectal cancer cells has been

Oxaliplatin sensitizes human colon cancer cells to TRAIL ... - Tel - Hal

Apr 30, 2011 BACKGROUND amp AIMS: Oxaliplatin sensitizes drug-resistant colon were used to determine requirements for phosphorylation of Bcl-xL 5-Fluorouracil (5-FU) is commonly used to treat human colon cancers but resistance .. drug 5-FU resulted in selection of cells resistant to this agent, and Bcl-XL

Jan 22, 2002 found that high levels of anti-apoptotic Bcl-2 and Bcl-xL pro- 5-Fluorouracil (5- FU), the most commonly used drug in colon cancer therapy,2 is colon cancer. Resistance to apoptosis induction is now accepted as one of the mechanisms responsible for resis- tance to anti-cancer drugs,1) and the Bcl-2